Novo Nordisk has reached a settlement with Mylan Pharmaceuticals regarding the patent dispute over the weight loss drugs Ozempic and Wegovy. Novo Nordisk and Mylan Pharmaceuticals, a subsidiary of Viatris, announced in a joint document that they have agreed to resolve the patent dispute related to Novo Nordisk's weight loss drugs Ozempic and Wegovy. Previously, Novo Nordisk had separately sued Viatris and other companies in court for patent infringement to prevent the proposed generic drug. A spokesperson for Novo Nordisk confirmed the settlement agreement on October 7th local time.